Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation

Presented by

Prof. Federico Martinón-Torres , Instituto de Investigación Sanitaria, Spain

Conference

ESCMID Vaccines 2025

Nirsevimab immunisation in infants resulted in a reduction in the risk of recurrent hospitalisation due to respiratory infections and all-cause hospitalisation, according to a real-world analysis of over 12,000 infants in Spain.

Prof. Federico Martinón-Torres (Instituto de Investigación Sanitaria, Spain) presented results from the NIRSE-GAL (NCT06180993), a prospective, longitudinal, population-based study [1]. Between October 2023 and March 2024, infants born in Galicia, Spain, were offered a single dose of nirsevimab and were followed up for 18 months using electronic health records (two RSV seasons). Recurrent hospitalisations were defined as ≥2 hospitalisations, and outcomes were assessed for RSV-related lower respiratory tract infections (LRTIs), all-cause LRTIs, bronchitis/bronchiolitis, and all-cause hospitalisations. The effect of nirsevimab was estimated by comparison with historical data (2016-2023).

The final dataset included 12,492 children (N=11,796 immunised and 696 non-immunised). The overall risk reduction (RR) in recurrent RSV-related LRTI hospitalisation with nirsevimab was 85.5%, although significant RRs were seen only in the second season (78.2%, 2024-2025). Recurrent all-cause LRTI hospitalisations were significantly reduced in both seasons, with an RR of 75.5% overall, 74.7% for the first season, and 62.4% for the second season. Furthermore, recurrent hospitalisations due to acute bronchitis/bronchiolitis were significantly reduced following nirsevimab immunisation, with RRs of 81.6%, 75.9%, and 76.9% overall, and for the first and second seasons, respectively. Similarly, risk reduction was seen for all-cause recurrent hospitalisations, corresponding to RRs of 16%, 29%, and 7.4% (not significant for the second season).

“Universal administration of nirsevimab as part of a regional or national programme significantly reduced the burden of recurrent hospitalisations due to RSV specifically, but also due to lower respiratory tract infections and bronchiolitis,” said Prof. Martinón-Torres. “We think these findings are important for healthcare planning and for evaluating the implementation of prophylaxis against RSV.”

Razzini JL, et al. Impact of universal nirsevimab immunisation on recurrent RSV-related hospitalisations across 2 consecutive RSV seasons: NIRSE-GAL study. 6th ESCMID Vaccines, 10–13 September 2025, Lisbon, Portugal.

Medical Conferences

Infants immunised with nirsevimab have a lower risk of respiratory-related recurrent hospitalisation

Table of Contents: ESCMID Vaccines 2025

Featured articles

Letter from the Editor

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

ESCMID Vaccines 2025 Highlights Podcast

Pneumococcal Vaccination

A quarter of US children have incomplete pneumococcal vaccination by age 2

V116 shows promise for adults at risk of pneumococcal disease

Real-world data confirm PCV20 effectiveness against pneumococcal disease in adults aged ≥65 years

The V116 pneumococcal vaccine is a new option in children at risk for pneumococcal disease

Influenza and COVID-19 Vaccination

Omicron XBB.1.5 vaccination provides effective, but rapidly waning protection in immunocompromised individuals

Intranasal COVID-19 vaccine shows promising results in preclinical mouse models

Influenza vaccine in children shows moderate, broad protection during the 2024-2025 season

Lower age is linked to reduced uptake of influenza and COVID-19 vaccination

RSV vaccination and Immunisation

Combination respiratory vaccines show promise but face key challenges

Adjuvanted RSVPreF3 demonstrates high real-world effectiveness in the USA

RSV immunisation: Maternal versus direct infant immunisation

European pregnant women show openness to maternal RSV vaccination